Growing Problem on Antibiotic Resistance, but There’s Also Reason for Hope

Dr. Ron Najafi, CEO of Emery Pharma Services joins eHealth Radio and the Health News and Pharmaceutical Channels to discuss the alarming concerns about super bugs such as Methicillin Resistance Staphylococcus Aureus (MRSA) and how it’s affecting our global health.
Listen to interview with host Eric Michaels & guest Dr. Ron Najafi discuss the following:

• How has antibiotic resistance become a growing worldwide public health crisis? Who is to blame for this problem?
• What are Staphylococcus aureus infections and how are they easily acquired in places like hospitals -- which are meant to keep us healthy?
• Why are researchers having a hard time replacing the existing arsenal of effective antimicrobial agents?
• Your company works with companies addressing this problem, what new breakthroughs do you find promising? 
• What can we be doing as patients to also curb the problem? What safeguards can we take?

Duration: 17:21
After earning a B.S. and M.S. in chemistry at the University of San Francisco, Ron Najafi received his Ph.D. at University of California at Davis. He worked at Sigma-Aldrich, Rhone Poulenc Rorer (now Sanofi), and PerkinElmer-Applied Biosystems before leaving to found CP Lab Safety and NovaBay Pharmaceuticals.  Dr. Najafi is an innate innovator. With more than 50 patents & pending patent applications, including a class of non-antibiotic, antimicrobial compounds named Aganocides®. The leading molecule of this aganocide family of compounds, auriclosene, has a broad spectrum of antimicrobial activity against bacteria, viruses and fungi.
Ron Najafi championed development of NeutroPhase for wound care. In September 2013, working together with John Crew, MD (vascular surgeon) they developed Crew-NovaBay minimally invasive surgical procedure to treat flesh eating bacteria. NeutroPhase has been successfully used in over 40 cases diagnosed as flesh eating infection. NeutroPhase has shown in a number of critical scientific publications to neutralize the key toxins responsible for the flesh eating disease. In 2014, Ron Najafi and her sister, Kathryn (Katy) Najafi, MD (Ophthalmologist & Surgeon) discovered a unique formulation of NeutroPhase to help manage patients suffering from Blepharitis. This unique formulation was initially called i-Lid Cleanser and later changed name to AVENOVA.

Website: www.emerypharmaservices.com
Social Media Links:
Facebook: www.facebook.com/pages/Emeryville-Pharmaceutical-Services
Twitter: @EmeryvillePharm

Are you enjoying the podcast? Please, leave a review.